FDAnews
FDAnews Drug Daily Bulletin

KOS AND JERINI SIGN EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT

Nov. 8, 2005

Kos Life Sciences, Inc., a subsidiary of Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) and Jerini U.S. Inc., a subsidiary of Jerini AG (FSE:JI4), announced today the signing of an exclusive agreement for the development, marketing and distribution of Jerini's compound, Icatibant, a potent and specific peptidomimetic bradykinin B2 receptor antagonist, in the United States and Canada. The strategic partnership includes an upfront licensing payment of EUR 12 million (approx. $15 million), along with a EUR 10 million (approx. $12 million) equity investment out of a capital increase at the higher of the weighted average of the closing price of Jerini's shares during the last four trading days, or EUR 3.20 (approx. $3.84) per share (IPO price).

PrimeZone (http://www.primezone.com/newsroom/news.html?d=89274)